Skip to main content
Clinical Trials/NCT03486925
NCT03486925
Completed
Not Applicable

An Eye-tracking Study to Investigate Oxytocin Effect on Attention Inhibition

University of Electronic Science and Technology of China1 site in 1 country71 target enrollmentDecember 19, 2017

Overview

Phase
Not Applicable
Intervention
oxytocin treatment
Conditions
Healthy
Sponsor
University of Electronic Science and Technology of China
Enrollment
71
Locations
1
Primary Endpoint
emotion-specific saccade latencies
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

Effects of intranasal oxytocin (24IU) on cognitive control of attention

Detailed Description

The cognitive control of attention towards neutral and emotional stimuli represents a key functional domain and disruptions in this domain have been associated with a range of psychiatric disorders. Saccadic eye movement tasks have been used to assess individual differences in the cognitive control of attention and alterations in psychiatric disorders. Recent evidence suggests that the hypothalamic neuropeptide Oxytocin (OXT) may modulate attention allocation and regulation. To this end the present randomized between-subject placebo-controlled experiment examined whether intranasal OXT modulates behavior in an eye-tracking saccade / anti-saccade paradigm in healthy male subjects. The paradigm used non-social (neutral shape) as well as social (happy, sad, angry, fear, and neutral faces) stimuli to explore emotion-specific effects of OXT.

Registry
clinicaltrials.gov
Start Date
December 19, 2017
End Date
August 28, 2018
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Male

Investigators

Sponsor
University of Electronic Science and Technology of China
Responsible Party
Principal Investigator
Principal Investigator

Benjamin Becker

Professor

University of Electronic Science and Technology of China

Eligibility Criteria

Inclusion Criteria

  • Male, healthy participants
  • Non smokers

Exclusion Criteria

  • Previous or current medical, psychiatric, neurological disorder
  • Regular medication
  • Use of any psychoactive substances in the 24 hours before experiment
  • Contra-indications for oxytocin
  • Contra-indications for eye-tracking data acquisition

Arms & Interventions

oxytocin group

Intervention: oxytocin treatment

placebo group

Intervention: placebo treatment

Outcomes

Primary Outcomes

emotion-specific saccade latencies

Time Frame: 45 minutes - 100 minutes after treatment

comparison between emotion-specific saccade latencies between the treatment groups (in milliseconds)

emotion-specific error rates

Time Frame: 45 minutes - 100 minutes after treatment

comparison between the emotion-specific ratio of unsuccessful anti-saccades between the treatment groups.

Study Sites (1)

Loading locations...

Similar Trials